drugset / Trial / NCT07502521
Dexrazoxane to Protect Against Hemorrhagic STEMI
Non-randomizedSequentialDouble-blindTreatment
Summary
This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
Timeline
- Start
- 2025-08-30
- Primary completion
- 2026-02-15
- Completion
- 2026-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexrazoxane | Small molecule | — | Intravenous |